Drugs Made In America Acquisition II Corp

Research Drugs Made In America Acquisition II Corp (DMII) on Bullrun: valuation model: 13.0% overvalued, market cap USD 641.46M, P/E 75.1. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerDMII
• ExchangeNASDAQ
• CountryUnited States
• SectorFinancial Services
• IndustryShell Companies
• CurrencyUSD
• Valuation signal13.0% overvalued
• Market capUSD 641.46M
• P/E75.1
• Financial periodFY2025
• Net incomeUSD 4.19M

Valuation Snapshot

Bullrun's latest valuation model marks Drugs Made In America Acquisition II Corp as 13.0% overvalued; latest market cap is USD 641.46M; P/E is 75.1.

About Drugs Made In America Acquisition II Corp

Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.

Frequently asked questions

Is Drugs Made In America Acquisition II Corp overvalued or undervalued?

Bullrun's valuation model currently marks Drugs Made In America Acquisition II Corp as 13.0% overvalued.

What is Drugs Made In America Acquisition II Corp's market cap?

Drugs Made In America Acquisition II Corp's market capitalization is USD 641.46M.

What is Drugs Made In America Acquisition II Corp's P/E ratio?

Drugs Made In America Acquisition II Corp's price-to-earnings (P/E) ratio is 75.1.

What does Drugs Made In America Acquisition II Corp do?

Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses.